OBJECTIVES: To report the burden and cost of non-melanoma skin cancer (NMSC) treatments in Australia and to project estimates of numbers and costs to 2015. DESIGN AND SETTING: Retrospective study of data obtained from Medicare Australia for NMSC treated by excision, curettage, laser or cryotherapy between 1 January 1997 and 31 December 2010, by year, sex, age group and state or territory. MAIN OUTCOME MEASURES: Total number, total Medicare Benefits Schedule (MBS) benefit and total cost in Australian dollars of NMSC treatments. RESULTS: The total number of NMSC treatments increased from 412 493 in 1997 to 767 347 in 2010, and we estimated that the number of treatments would increase to 938 991 (95% CI, 901 047-976 934) by 2015. The total MBS benefit for NMSC treatments in 2010 was $93.5 million, and we estimated that this will increase to $109.8 million (95% CI, $105.9-$113.7 million) by 2015, whereas the total cost with inflation (ie, cost which includes diagnosis, treatment and pathology) was $511.0 million in 2010, estimated to increase to $703.0 million (95% CI, $674.6-$731.4 million) by 2015. CONCLUSION: NMSC treatments increased by 86% between 1997 and 2010. We anticipate that the number and the total cost without inflation of NMSC treatments will increase by a further 22% between 2010 and 2015. NMSC will remain the most costly cancer and place an increasing burden on the Australian health care system.
OBJECTIVES: To report the burden and cost of non-melanoma skin cancer (NMSC) treatments in Australia and to project estimates of numbers and costs to 2015. DESIGN AND SETTING: Retrospective study of data obtained from Medicare Australia for NMSC treated by excision, curettage, laser or cryotherapy between 1 January 1997 and 31 December 2010, by year, sex, age group and state or territory. MAIN OUTCOME MEASURES: Total number, total Medicare Benefits Schedule (MBS) benefit and total cost in Australian dollars of NMSC treatments. RESULTS: The total number of NMSC treatments increased from 412 493 in 1997 to 767 347 in 2010, and we estimated that the number of treatments would increase to 938 991 (95% CI, 901 047-976 934) by 2015. The total MBS benefit for NMSC treatments in 2010 was $93.5 million, and we estimated that this will increase to $109.8 million (95% CI, $105.9-$113.7 million) by 2015, whereas the total cost with inflation (ie, cost which includes diagnosis, treatment and pathology) was $511.0 million in 2010, estimated to increase to $703.0 million (95% CI, $674.6-$731.4 million) by 2015. CONCLUSION: NMSC treatments increased by 86% between 1997 and 2010. We anticipate that the number and the total cost without inflation of NMSC treatments will increase by a further 22% between 2010 and 2015. NMSC will remain the most costly cancer and place an increasing burden on the Australian health care system.
Authors: A F Bais; R M Lucas; J F Bornman; C E Williamson; B Sulzberger; A T Austin; S R Wilson; A L Andrady; G Bernhard; R L McKenzie; P J Aucamp; S Madronich; R E Neale; S Yazar; A R Young; F R de Gruijl; M Norval; Y Takizawa; P W Barnes; T M Robson; S A Robinson; C L Ballaré; S D Flint; P J Neale; S Hylander; K C Rose; S-Å Wängberg; D-P Häder; R C Worrest; R G Zepp; N D Paul; R M Cory; K R Solomon; J Longstreth; K K Pandey; H H Redhwi; A Torikai; A M Heikkilä Journal: Photochem Photobiol Sci Date: 2018-02-14 Impact factor: 3.982
Authors: Ali Azimi; Kimberley L Kaufman; Marina Ali; Steven Kossard; Pablo Fernandez-Penas Journal: Cancer Genomics Proteomics Date: 2016 11-12 Impact factor: 4.069
Authors: Louisa G Gordon; Astrid J Rodriguez-Acevedo; Brian Køster; Gery P Guy; Craig Sinclair; Emilie Van Deventer; Adèle C Green Journal: JAMA Dermatol Date: 2020-04-01 Impact factor: 10.282
Authors: Yang Wu; Simon Ghaly; Stephen Kerr; Bryce Jackson; Katherine Hanigan; Deborah Martins; Krupa Krishnaprasad; Reme E Mountifield; David C Whiteman; Peter A Bampton; Richard B Gearry; Graham L Radford-Smith; Ian C Lawrance Journal: Dig Dis Sci Date: 2019-09-06 Impact factor: 3.199
Authors: A Stang; L Khil; H Kajüter; N Pandeya; C D Schmults; E S Ruiz; P S Karia; A C Green Journal: J Eur Acad Dermatol Venereol Date: 2019-12 Impact factor: 6.166
Authors: Michelle T Sun; Andrea J O'Connor; Imogen Milne; Dhee Biswas; Robert Casson; John Wood; Dinesh Selva Journal: Tissue Eng Regen Med Date: 2019-07-26 Impact factor: 4.169
Authors: David C Whiteman; Penelope M Webb; Adele C Green; Rachel E Neale; Lin Fritschi; Christopher J Bain; D Max Parkin; Louise F Wilson; Catherine M Olsen; Christina M Nagle; Nirmala Pandeya; Susan J Jordan; Annika Antonsson; Bradley J Kendall; Maria Celia B Hughes; Torukiri I Ibiebele; Kyoko Miura; Susan Peters; Renee N Carey Journal: Aust N Z J Public Health Date: 2015-10 Impact factor: 2.939